KRAS and non-small cell lung carcinoma: In contrast, mKRAS and co-occurring STK11- and KEAP1-mutant tumors had reduced PD-L1 expression, suggesting that the addition of bevacizumab to atezolizumab may represent the preferred option for KRAS and TP53 co-mutated NSCLC [55].